It wasn’t that industry was putting off having these conversations – most of industry didn’t even know that such a conversation was needed. It would have been like someone living in a bungalow wondering what colour they should paint the upstairs bathroom.

Mercifully, these conversations are starting – and they are rainbow-coloured. There is now a greater motivation to form clinical trial groups that reflect society – not just the type of people that typically enter clinical trials. Industry is embracing difference.

Inclusivity in a medical setting has benefits that not only provide greater insights into specific therapies, but also indicate the wider mental impact of taking particular treatments, how they affect different social groups and what it all means when it comes to reducing health inequalities.

There is also a global aspect to clinical trial inclusivity and it involves the parity of people. If people feel self-worth and are treated with dignity, they make better life choices. And when people make positive decisions because they feel validated, they are more likely to be healthier. Thus, the entire global healthcare ecosystem starts firing on all cylinders.

It is a myth that conversations about inclusion have to be awkward. Having them and acting on them actually reduces awkwardness by well over 100%.

Enjoy the magazine,

John Pinching
editor

PharmaTimes Media Ltd,
Mansard House, Church Road,
Little Bookham, Surrey, KT23 3JG
Tel: +44 (0)20 7240 6999
www.pharmatimes.com Twitter: @PharmaTimes

EDITORIAL
John Pinching / editor
john.pinching@pharmatimes.com

Iona Everson / group managing editor
iona.everson@pharmatimes.com

Karl Equi / executive director
karl.equi@pharmatimes.com  

SALES & MARKETING
Tara Lovegrove / business director
tara.lovegrove@pharmatimes.com

Luci Sargood / business manager
luci.sargood@pharmatimes.com

SUBSCRIPTIONS/REPRINTS
Digital and paper copies available free to qualifying readers: www.pharmatimes.com/subscribe
Tel: 01372 414 222
subscriptions@pharmatimes.com
Paper subscriptions available at £90.00 UK and £100.00 overseas per annum.

Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.

Material may not be reproduced in any form without the publisher’s written permission. © Copyright 2022 PharmaTimes Magazine. All rights reserved. PharmaTimes Magazine is published by PharmaTimes Media Ltd, which is registered as a limited company in England; No 09019637.